- Zai Lab Limited (NASDAQ:ZLAB) is set for its $115M IPO of ordinary shares.
- The Shanghai, China-based biopharmaceutical firm develops proprietary therapeutics to address large unmet medical needs in China.
- Its lead candidate is PARP inhibitor ZL-2306, currently being evaluated in several cancers, including breast and ovarian. Candidate #2 is broad-spectrum antibiotic omadacycline (ZL-2401) for the treatment of ABSSSI, CABP and urinary tract infections. Candidate #3 is cancer candidate ZL-2301 (brivanib), a dual inhibitor of VEGF and FGF (fibroblast growth factor) receptors.
- 2016 Financials ($M): Operating Expenses: (38.5) (+136.2%); Net Loss: (37.5) (-108.3%); Cash Burn: (32.2) (-180.0%).
Zai Lab on deck for IPO
Recommended For You
About ZLAB Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ZLAB | - | - |
Zai Lab Limited |